Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2022 Net Income-$2.08M-$2.08MN/M vs Q3 2022 EPS Diluted-$1.54-$1.54N/M vs Q3 2022 Operating Income-$2,167,612N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,760,939N/M ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end